Small-cap stock below ₹50 sets date to declare Q4 results 2025, final dividend for FY25
BCL Industries Limited informed the exchanges that the board meeting is slated to take place next week on May 29 to declare Q4 results and final dividend.
The small-cap stock in an exchange filing said, 'A meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 29th day of May, 2025.'
The agenda of the board meeting of BCL Industries is to consider and approve the audited financial results (Standalone and Consolidated) of the company for the quarter and year ended on 31st March 2025.
The board of BCL Industries will also consider and recommend the dividend (if any) for the financial year 2024-25 during its meeting on Thursday, May 29.
As per the release by BCL Industries, the 'Trading Window' for dealing in securities of the company was closed on 1st April, 2025 and shall remain closed till 48 hours after the declaration of the Unaudited Financial Results and becoming generally available to the public at large.
Small-cap stock below ₹ 50, BCL Industries share price, opened at ₹ 40.30 on the BSE on Friday, higher than the previous day's closing price of ₹ 39.73. Thereafter, BCL Industries share price continued trading in the green.
BCL Industries stock had corrected sharply from a 52-week or one-year high of ₹ 68.83 touched in September 2024 to a 52-week or one-year low of ₹ 33 in April 2025 amid a correction in the broader markets. However, the small-cap stock has been rebounding well of late.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
14 minutes ago
- Business Standard
Sun Pharma Q1 net profit falls 20% Y-o-Y; revenue rises 9%
Litigation, drug discontinuation weigh on earnings; US market remains sluggish even as India sales and Leqselvi launch boost specialty push Sun Pharmaceutical, India's largest drugmaker, has posted a decline of 20 per cent year-on-year (Y-o-Y) in its consolidated net profit for the first quarter of 2025-26 (Q1FY26). While its net profit was ₹2,278 crore, its revenue from operations rose 9 per cent at ₹13,851 crore. The fall in profit is primarily because of discontinuing the development of SCD-044, an investigational drug (₹287.6 crore), and a litigation settlement involving Taro and SPIINC (₹530.3 crore). This was despite an exceptional tax credit of ₹100.5 crore. Sequentially net profit rose 6 per cent with revenue rising 7 per cent. The muted performance in the United States (US), the company's largest overseas market, is a key concern, with formulation sales there up only 1.5 per cent Y-o-Y at $473 million, contributing 29 per cent to consolidated revenues. 'The US launch of Leqselvi represents an important step forward, offering a new treatment option for patients with severe alopecia areata,' said Chairman and Managing Director Dilip Shanghvi. He added that Leqselvi strengthened Sun's dermatology franchise and was expected to be a growth driver. The results came during market hours. Sun's stock fell 1.6 per cent, ending the day's trade at ₹1,705.5 on the BSE. Shanghvi said: 'The launch of Leqselvi represents an important step forward, offering a new treatment option for patients with severe alopecia areata. Leqselvi augments our portfolio in dermatology and adds a growth engine to our innovative medicines business.' Formulation sales in India stood at ₹4,721 crore, up 14 per cent Y-o-Y, contributing 34 per cent to consolidated sales for the quarter. Sun Pharma retained its number 1 ranking in the Indian pharmaceutical market, with market share rising from 8 per cent to 8.3 per cent, according to Pharmarack MAT June 2025 data. The company launched five products during April-June.
News18
39 minutes ago
- News18
Axis Solutions debuts on BSE after completing merger
Agency: PTI Last Updated: New Delhi, Jul 31 (PTI) Axis Solutions, formerly known as Asya Infosoft, on Thursday said it has completed its merger and listed its equity shares on the BSE. The company offers industrial automation and digital infrastructure solutions. The listing follows the implementation of a resolution plan and marks a strategic milestone, Axis Solutions said in a statement. 'The commencement of listing & trading on the BSE makes a significant milestone in our strategic transformation and marks the start of a focused journey toward expansion and innovation. 'This listing not only enhances our visibility in the capital markets but also strengthens investor engagement as we pursue our vision for accelerated growth in both domestic and international markets," Axis Solutions' MD Bijal Sanghvi, said. view comments First Published: July 31, 2025, 22:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
an hour ago
- Mint
Vedanta Q1 profit falls 11%; Co drops plan to tap strategic reserves
Mumbai: Vedanta Ltd's profit for the April-June period fell by over a tenth from a year ago due to higher tax expenses, even as it produced the most zinc and alumina ever for a first fiscal quarter. The metals and mining major has shelved its plans to transfer ₹ 12,587 crore from its strategic reserves to retained earnings, the total profits that a company keeps after distributing dividends to shareholders. The move was seen as an attempt by the company to free up cash by liquidating reserves to increase the dividend outgo to its shareholders, including its London-based parent company Vedanta Resources. Vedanta had earlier moved the Mumbai bench of the National Company Law Tribunal to seek its nod on the transaction. 'In view of evolving strategic priorities, the Board of Directors, at its meeting held today, has decided not to pursue the aforesaid Scheme at this stage,' the company said in a regulatory filing on Thursday. The company's board also approved an additional $84 million for the expansion of its zinc mines at Gamsberg in South Africa. Earlier, it had approved a $466 million plan to double the mine's capacity from 4 million tonnes a year. With the additional investment, the capacity will be ramped up to 8.4 million tonnes a year, making Vedanta Zinc International the largest Zinc producer in South Africa, the company said. Vedanta Ltd reported a profit of ₹ 3,185 crore, lower than ₹ 3,606 crore a year ago. The corresponding quarter last year had a deferred tax gain of ₹ 735 crore, which turned to a ₹ 206 crore outgo this year, impacting its bottom line. Its revenue for the quarter was 6% higher year-on-year at ₹ 37,434 crore. The company's stock closed 2.16% lower at ₹ 425.3 on the BSE on Thursday. The earnings were disclosed during trading hours. 'Our 1Q performance has set a strong foundation for the year ahead. Amidst global market volatility, we delivered the highest-ever first quarter Ebitda,' Anil Agarwal, chairman, Vedanta, said in a press statement. The company reported earnings before interest, tax, depreciation and amortization (Ebitda) of ₹ 9,528 crore, up 1% year-on-year. 'This strong performance alongside corporate initiatives, such as the HZL stake sale which generated ₹ 3028 crore cash, has enabled Vedanta to deliver a Net Debt to EBITDA ratio of 1.3x,' said Ajay Goel, chief financial officer of the company. 'Given our NCD (non-convertible debenture) issuance of ₹ 5,000 crore and other refinancing, the cost of our debt has reduced by around 130bps y-o-y to 9.2%. The recent reaffirmation in credit rating at AA by both Crisil and ICRA highlights our financial strength and market's confidence in Vedanta's growth story,' he said.
